pfn-1 Antibody

FAQs for PFN1 Antibody Research (Academic Focus)

Advanced Research Questions

How does PFN1 phosphorylation at Ser71 influence its tumor-suppressive function?

• Mechanistic insights:

  • Phosphorylation at Ser71 disrupts actin binding, enabling nuclear retention of PFN1 for transcriptional repression .

  • Both phospho-resistant (S71A) and phosphomimetic (S71D) mutants fail to inhibit tumor growth, suggesting dynamic cycling is essential .

• Experimental design:

  • Use MDA-MB-231 xenografts transfected with PFN1 mutants to assess tumor growth .

  • Monitor nuclear-cytoplasmic shuttling via live-cell imaging with tagged PFN1 .

How to resolve contradictions in PFN1’s role as tumor suppressor vs. metastasis promoter?

• Analysis framework:

  • Context-dependent roles:

    • Tumor suppression: Linked to nuclear PFN1-mediated transcriptional repression (e.g., c-MYC downregulation) .

    • Metastasis promotion: Associated with cytoplasmic PFN1-ROCK1 interaction driving microvesicle secretion .

  • Experimental variables:

    • Cell type (e.g., triple-negative breast vs. NSCLC) .

    • Phosphorylation status (e.g., pSer71 vs. pSer137) .

What technical challenges arise when studying endogenous PFN1 in low-abundance systems?

• Solutions:

  • Enrichment techniques: Use PLP-conjugated agarose beads for PFN1 pulldown from whole-cell lysates .

  • Signal amplification: Employ tyramide-based IHC protocols for low-expressing tissues .

  • Multiplex assays: Combine IF with proximity ligation assays (PLA) to study PFN1-protein interactions .

How to integrate PFN1 antibody data with omics datasets for biomarker discovery?

• Workflow:

  • Cross-reference IHC data with TCGA RNA-seq profiles (e.g., PFN1 mRNA levels in metastatic LUAD) .

  • Validate candidate biomarkers using orthogonal methods (e.g., mass spectrometry for phosphorylation sites) .

  • Apply machine learning to correlate PFN1 expression with clinical outcomes (e.g., survival analysis in NSCLC) .